Abstract
α-Glucosidase inhibitors are marketed as therapeutic drugs for diabetes that act through the inhibition of carbohydrate metabolism. Inhibitors of the α-glucosidases that are involved in the biosynthesis of N-linked oligosaccharide chains have been reported to have antitumor, antiviral, and apoptosis-inducing activities, and some have been used clinically. α-Glucosidase inhibitors have interesting biological activities, and their design, synthesis, and screening are being actively performed. In quite a few reports, however, α-glucosidases with different origins than the target α-glucosidases, have been used to evaluate inhibitory activities. There might be confusion regarding the naming of α-glucosidases. For example, the term α-glucosidase is sometimes used as a generic name for α-glucoside hydrolases. Moreover, IUBMB recommends the use of “α-glucosidase” (EC 3.2.1.20) for exo-α-1,4-glucosidases, which are further classified into four families based on amino acid sequence similarities. Accordingly, substrate specificity and susceptibility to inhibitors varies markedly among enzymes in the IUBMB α-glucosidases. The design and screening of inhibitors without consideration of these differences is not efficient. For the development of a practical inhibitor that is operational in cells, HTS using the target α-glucosidase and the computer-aided design of inhibitors based on enzymatic information concerning the same α-glucosidase are essential.
Keywords: α-glucosidase, substrate specificity, inhibitor, HTS, virtual screening, in silico, structure based drug design
Current Topics in Medicinal Chemistry
Title: Design and Screening Strategies for α-Glucosidase Inhibitors Based on Enzymological Information
Volume: 9 Issue: 1
Author(s): Wataru Hakamata, Masaaki Kurihara, Haruhiro Okuda, Toshiyuki Nishio and Tadatake Oku
Affiliation:
Keywords: α-glucosidase, substrate specificity, inhibitor, HTS, virtual screening, in silico, structure based drug design
Abstract: α-Glucosidase inhibitors are marketed as therapeutic drugs for diabetes that act through the inhibition of carbohydrate metabolism. Inhibitors of the α-glucosidases that are involved in the biosynthesis of N-linked oligosaccharide chains have been reported to have antitumor, antiviral, and apoptosis-inducing activities, and some have been used clinically. α-Glucosidase inhibitors have interesting biological activities, and their design, synthesis, and screening are being actively performed. In quite a few reports, however, α-glucosidases with different origins than the target α-glucosidases, have been used to evaluate inhibitory activities. There might be confusion regarding the naming of α-glucosidases. For example, the term α-glucosidase is sometimes used as a generic name for α-glucoside hydrolases. Moreover, IUBMB recommends the use of “α-glucosidase” (EC 3.2.1.20) for exo-α-1,4-glucosidases, which are further classified into four families based on amino acid sequence similarities. Accordingly, substrate specificity and susceptibility to inhibitors varies markedly among enzymes in the IUBMB α-glucosidases. The design and screening of inhibitors without consideration of these differences is not efficient. For the development of a practical inhibitor that is operational in cells, HTS using the target α-glucosidase and the computer-aided design of inhibitors based on enzymatic information concerning the same α-glucosidase are essential.
Export Options
About this article
Cite this article as:
Hakamata Wataru, Kurihara Masaaki, Okuda Haruhiro, Nishio Toshiyuki and Oku Tadatake, Design and Screening Strategies for α-Glucosidase Inhibitors Based on Enzymological Information, Current Topics in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/156802609787354306
DOI https://dx.doi.org/10.2174/156802609787354306 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities: A Review
Current Medical Imaging DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Promising Therapies for Alzheimer's Disease
Current Pharmaceutical Design Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology A Short Course on Virology / Vectorology / Gene Therapy
Current Gene Therapy In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Current Pharmaceutical Biotechnology Contemporary Role of Endocrine Treatment in Patients with Localized or Locally Advanced Prostate Cancer: A Review
Current Cancer Therapy Reviews Novel Hybrid Molecules of Quinazoline Chalcone Derivatives: Synthesis and Study of in vitro Cytotoxic Activities
Letters in Drug Design & Discovery Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis and Biological Evaluations of Organoruthenium Scaffolds: A Comprehensive Update
Current Organic Synthesis Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design ZIP4 is a Novel Diagnostic and Prognostic Marker in Human Pancreatic Cancer: A Systemic Comparison Between EUS-FNA and Surgical Specimens
Current Molecular Medicine Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry Hypoxic Culture Conditions for Mesenchymal Stromal/Stem Cells from Wharton’s Jelly: A Critical Parameter to Consider in a Therapeutic Context
Current Stem Cell Research & Therapy Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Meet Our Editorial Board Member:
Current Medicinal Chemistry